Altum International chief executive Ean Alexander has called for the industry to fund a dedicated unit within the Therapeutic Goods Administration (TGA) in a move to better monitor and police the sector.
Amid a slew of negative media coverage in recent weeks, he said now was the time to strengthen industry standards and ensure cannabis remains accessible to patients.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh.
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh.
Elementum integer enim neque volutpat ac tincidunt vitae semper quis. Eu lobortis elementum nibh tellus molestie nunc. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Magnis dis parturient montes nascetur ridiculus. Dui id ornare arcu odio ut sem. Nisl nunc mi ipsum faucibus vitae.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
This would benefit all stakeholders. TGA creating a Complementary Medicines Branch was of huge benefit and medicinal cannabis has unique regulatory challenges, in a similar way to what comp meds have, that would be best supported by a specialist team at TGA.
Hear, hear!
I agree, in addition to looking at the sales and marketing pipe, the lack of scrutiny on imports means a lot of companies have very limited understanding of what a fully GMP compliant product ACTUALLY looks like.
Going over the dossiers with a fine tooth comb could delete half the products available, making things more viable for the remaining good suppliers/products, and reducing the commercial desperation that leads to dirty deals.